Wee Joo Chng


Affiliation: National University of Singapore
Country: Singapore


  1. Mahara S, Lee P, Feng M, Tergaonkar V, Chng W, Yu Q. HIFI-? activation underlies a functional switch in the paradoxical role of Ezh2/PRC2 in breast cancer. Proc Natl Acad Sci U S A. 2016;113:E3735-44 pubmed publisher
    ..Our study suggests a tumor-suppressive function of PRC2, which is restricted by HIF1-?, and an oncogenic function of Ezh2, which cooperates with FoxM1 to promote invasion in triple-negative breast cancer. ..
  2. de Mel S, Hue S, Jeyasekharan A, Chng W, Ng S. Molecular pathogenic pathways in extranodal NK/T cell lymphoma. J Hematol Oncol. 2019;12:33 pubmed publisher
  3. Xie Z, Chooi J, Toh S, Yang D, Basri N, Ho Y, et al. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells. Leukemia. 2019;33:739-748 pubmed publisher
    ..This suggested that GLO1 may be of functional importance target downstream of MMSET I. Cumulatively, our study suggests that MMSET I is an oncoprotein and potential therapeutic target for t(4;14) MM. ..
  4. Chong P, Zhou J, Chooi J, Chan Z, Toh S, Tan T, et al. Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia. Oncogene. 2019;38:1508-1519 pubmed publisher
    ..Our study presents a new avenue of cancer inhibition driven by PRL-3 overexpression or β-catenin hyperactivation. ..
  5. Arora L, Kumar A, Arfuso F, Chng W, Sethi G. The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. Cancers (Basel). 2018;10: pubmed publisher
    ..e., proliferation, differentiation, migration, and apoptosis of hematological malignancies viz. leukemia, lymphoma and myeloma, and briefly highlights the potential therapeutic approaches developed against STAT3 activation pathway. ..
  6. Zhou J, Ng Y, Chng W. ENL: structure, function, and roles in hematopoiesis and acute myeloid leukemia. Cell Mol Life Sci. 2018;75:3931-3941 pubmed publisher
    ..This review will not only provide a fundamental understanding of the structure and function of ENL and update on the roles of ENL in AML, but also the development of new therapeutic strategies. ..
  7. Teoh P, An O, Chung T, Chooi J, Toh S, Fan S, et al. Aberrant hyperediting of myeloma transcriptome by ADAR1 confers oncogenicity and is a marker of poor prognosis. Blood. 2018;: pubmed publisher
    ..Collectively, our data demonstrated that ADAR1-mediated-A-to-I editing is both clinically and biologically relevant in MM. These data unraveled novel insights into MM molecular pathogenesis at the global RNA level. ..
  8. Zhou Y, Zhou J, Lu X, Tan T, Chng W. BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia. BMC Cancer. 2018;18:731 pubmed publisher
    ..These findings provide novel insight on how BET inhibitor can induce apoptosis in AML, and further support the development of BET inhibitors as a promising therapeutic strategy against AML. ..
  9. de Mel S, Soon G, Mok Y, Chung T, Jeyasekharan A, Chng W, et al. The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation. Int J Mol Sci. 2018;19: pubmed publisher
    ..Herein, we present an overview of the molecular biology and genomic landscape of ENKTL with a focus on the most promising translational opportunities. ..

More Information


  1. Zhou J, Toh S, Chan Z, Quah J, Chooi J, Tan T, et al. A loss-of-function genetic screening reveals synergistic targeting of AKT/mTOR and WTN/β-catenin pathways for treatment of AML with high PRL-3 phosphatase. J Hematol Oncol. 2018;11:36 pubmed publisher
    ..Simultaneous inhibition of these two pathways could achieve robust clinical efficacy for this subtype of AML patient with high PRL-3 expression and warrant further clinical investigation. ..
  2. Soekojo C, de Mel S, Ooi M, Yan B, Chng W. Potential Clinical Application of Genomics in Multiple Myeloma. Int J Mol Sci. 2018;19: pubmed publisher
    ..In this review paper we describe the different genomic techniques available, including the latest advancements, and discuss the potential clinical application of genomics in multiple myeloma. ..
  3. Gupta N, Goh Y, Min C, Lee J, Kim K, Wong R, et al. Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. J Hematol Oncol. 2015;8:103 pubmed publisher
    ..0 mg. Consequently, East Asian patients enrolled in phase 3 studies are receiving the same ixazomib dose as patients in other regions. This study is registered at NCT01645930. ..
  4. Zhou J, Chan Z, Bi C, Lu X, Chong P, Chooi J, et al. LIN28B Activation by PRL-3 Promotes Leukemogenesis and a Stem Cell-like Transcriptional Program in AML. Mol Cancer Res. 2017;15:294-303 pubmed publisher
    ..b>Implications: The current study offers a rationale for targeting PRL-3 as a therapeutic approach for a subset of AML patients with poor prognosis. Mol Cancer Res; 15(3); 294-303. ©2016 AACR. ..
  5. Chai J, Zhang Y, Tan W, Chng W, Li B, Wang X. Regulation of hTERT by BCR-ABL at multiple levels in K562 cells. BMC Cancer. 2011;11:512 pubmed publisher
    ..Given that BCR-ABL is the specific target of Gleevec in CML treatment, we investigated the regulation of the catalytic component of telomerase, hTERT, by BCR-ABL at multiple levels in K562 cells...
  6. Chng W, Huang G, Chung T, Ng S, Gonzalez Paz N, Troska Price T, et al. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011;25:1026-35 pubmed publisher
    ..Bortezomib treatment is able to overcome the survival disadvantage in patients with MYC activation. ..
  7. Zhou J, Bi C, Ching Y, Chooi J, Lu X, Quah J, et al. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia. J Hematol Oncol. 2017;10:138 pubmed publisher
    ..In sum, these results uncover a novel mechanism of an important regulatory signaling, LIN28B/let-7/IGF2BP1, in leukemogenesis and provide a rationale to target this pathway as effective therapeutic strategy. ..
  8. Ng S, Ohshima K, Selvarajan V, Huang G, Choo S, Miyoshi H, et al. Prognostic implication of morphology, cyclinE2 and proliferation in EBV-associated T/NK lymphoproliferative disease in non-immunocompromised hosts. Orphanet J Rare Dis. 2014;9:165 pubmed publisher
    ..High cyclin E2 expression was also significantly associated with shorter survival (p = 0.0002). Our data suggests the potential role of monomorphic morphology, high cyclin E2 and Ki67 expression as adverse prognostic factors for TNKLPD. ..
  9. Zhou J, Chong P, Lu X, Cheong L, Bi C, Liu S, et al. Phosphatase of regenerating liver-3 is regulated by signal transducer and activator of transcription 3 in acute myeloid leukemia. Exp Hematol. 2014;42:1041-52.e1-2 pubmed publisher
    ..In conclusion, PRL-3 was transcriptionally regulated by STAT3. The STAT3/PRL-3 regulatory loop contributes to the pathogenesis of AML, and it might represent an attractive therapeutic target for antileukemic therapy. ..
  10. Chong P, Zhou J, Cheong L, Liu S, Qian J, Guo T, et al. LEO1 is regulated by PRL-3 and mediates its oncogenic properties in acute myelogenous leukemia. Cancer Res. 2014;74:3043-53 pubmed publisher
    ..In conclusion, we identify an important and novel mechanism by which PRL-3 mediates its oncogenic function in AML. ..